Metabolic interactions between adipose tissue and the heart may play an active role in progression of heart failure (HF). The aim of the study was to examine changes in myocardial and adipose tissue metabolism and gene expression in a rat HF model induced by chronic volume overload. HF was induced by volume overload from aorto-caval fistula (ACF) in 3-month-old male Wistar rats and animals were studied in the phase of decompensated HF (22nd week). HF rats showed marked eccentric cardiac hypertrophy, pulmonary congestion, increased LV end-diastolic pressure, and intraabdominal fat depletion. HF rats had preserved glucose tolerance, but increased circulating free fatty acids (FFA) and attenuated insulin response during oral glucose challenge. Isolated organ studies showed preserved responsiveness of adipose tissue lipolysis and lipogenesis to epinephrine and insulin in ACF. The heart of HF animals had markedly reduced triglyceride content (almost to half of controls), attenuated anti-oxidative reserve (GSH/GSSG), upregulated HF markers (ANP, periostin, thrombospondin-4), specific signaling pathways (Wnt, TGF-β), and downregulated enzymes of mitochondrial fatty acid oxidation, citric acid cycle, and respiratory chain. Adipose tissue transcription profiling showed upregulated receptor for gastric inhibitory polypeptide. In conclusion, ACF-induced HF model displays several deregulations of systemic metabolism. Despite elevation of systemic FFAs, myocardial triglycerides are low and insulin levels are attenuated, arguing against a role of lipotoxicity or insulin resistance in this model. Attenuated postprandial insulin response and relative lack of its antilipolytic effects may facilitate intraabdominal fat depletion observed in ACF-HF animals.

Department of Cardiology and Center for Cardiovascular Research Institute for Clinical and Experimental Medicine IKEM Videnska 1958 9 Prague 4 140 21 Czech Republic

See more in PubMed

J Clin Invest. 2010 Oct;120(10):3443-54 PubMed

Br Med J. 1970 May 16;2(5706):396-8 PubMed

Mol Cell Biochem. 1998 Mar;180(1-2):117-28 PubMed

Biochim Biophys Acta. 2010 Mar;1801(3):311-9 PubMed

Circulation. 1993 Mar;87(3):921-30 PubMed

Physiol Res. 2007;56(1):1-15 PubMed

Am J Physiol. 1996 Nov;271(5 Pt 2):H2071-8 PubMed

J Clin Invest. 1989 Jul;84(1):205-13 PubMed

Circ Res. 2009 Mar 27;104(6):805-12 PubMed

Cardiovasc Res. 2009 Feb 15;81(3):420-8 PubMed

J Am Coll Cardiol. 2007 Feb 20;49(7):811-21 PubMed

J Am Coll Cardiol. 2005 Sep 20;46(6):1019-26 PubMed

Eur J Heart Fail. 2006 Nov;8(7):687-93 PubMed

Trends Cardiovasc Med. 2002 Apr;12(3):134-8 PubMed

Circulation. 2001 Dec 11;104(24):2923-31 PubMed

Circulation. 1994 Jul;90(1):484-91 PubMed

Histochem Cell Biol. 2010 Feb;133(2):201-11 PubMed

Am J Physiol Heart Circ Physiol. 2001 Feb;280(2):H674-83 PubMed

J Clin Endocrinol Metab. 2005 May;90(5):2888-97 PubMed

Nat Med. 2003 Mar;9(3):352-5 PubMed

Cardiovasc Res. 1990 May;24(5):430-2 PubMed

Mol Cell Biochem. 2003 Sep;251(1-2):89-95 PubMed

Am J Cardiol. 1998 Jan 1;81(1):45-50 PubMed

Am J Physiol Heart Circ Physiol. 2010 Feb;298(2):H497-504 PubMed

Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1784-9 PubMed

Am J Physiol. 1992 Apr;262(4 Pt 2):H1068-74 PubMed

J Clin Invest. 2000 Jul;106(2):171-6 PubMed

J Biol Chem. 1991 May 5;266(13):8162-70 PubMed

Physiol Rev. 2005 Jul;85(3):1093-129 PubMed

Nat Genet. 2010 Feb;42(2):142-8 PubMed

Cell Mol Life Sci. 2000 Mar;57(3):429-40 PubMed

Physiol Rev. 2010 Jan;90(1):207-58 PubMed

FASEB J. 2004 Nov;18(14):1692-700 PubMed

J Mol Cell Cardiol. 2005 May;38(5):777-86 PubMed

Lancet. 1997 Apr 12;349(9058):1050-3 PubMed

J Lab Clin Med. 1976 Jun;87(6):1057-64 PubMed

Circulation. 2004 May 11;109(18):2240-5 PubMed

J Am Coll Cardiol. 2009 Oct 27;54(18):1637-46 PubMed

Am J Physiol Heart Circ Physiol. 2009 Apr;296(4):H1117-24 PubMed

Circulation. 2002 Jun 11;105(23):2701-3 PubMed

J Clin Endocrinol Metab. 2008 Feb;93(2):497-503 PubMed

Int J Obes (Lond). 2008 Dec;32(12):1848-53 PubMed

Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):499-512 PubMed

Metabolism. 1991 Sep;40(9):972-7 PubMed

J Biol Chem. 2009 Dec 25;284(52):36312-36323 PubMed

Clin Sci (Lond). 2011 Jul;121(1):29-41 PubMed

J Clin Invest. 1988 Mar;81(3):720-9 PubMed

Circulation. 2006 Nov 14;114(20):2130-7 PubMed

Circulation. 2007 Apr 17;115(15):2033-41 PubMed

Nucleic Acids Res. 2000 Jan 1;28(1):27-30 PubMed

Ann Thorac Surg. 2009 Dec;88(6):1916-21 PubMed

J Mol Cell Cardiol. 2008 Feb;44(2):315-22 PubMed

Am J Physiol Heart Circ Physiol. 2011 Jan;300(1):H125-34 PubMed

J Clin Invest. 2009 Apr;119(4):986-96 PubMed

J Cell Commun Signal. 2009 Dec;3(3-4):201-13 PubMed

Circulation. 2005 Nov 22;112(21):3280-8 PubMed

Anat Rec (Hoboken). 2011 Jan;294(1):102-11 PubMed

Am J Physiol. 1979 May;236(5):H698-704 PubMed

Circulation. 2010 Sep 7;122(10):993-1003 PubMed

The impact of phosphodiesterase-5 inhibition or angiotensin-converting enzyme inhibition on right and left ventricular remodeling in heart failure due to chronic volume overload

Anti-Fibrotic Potential of Angiotensin (1-7) in Hemodynamically Overloaded Rat Heart

New Porcine Model of Arteriovenous Fistula Documents Increased Coronary Blood Flow at the Cost of Brain Perfusion

Right versus left ventricular remodeling in heart failure due to chronic volume overload

Altered Renal Vascular Responsiveness to Vasoactive Agents in Rats with Angiotensin II-Dependent Hypertension and Congestive Heart Failure

Msx1 loss suppresses formation of the ectopic crypts developed in the Apc-deficient small intestinal epithelium

Effect of angiotensin-converting enzyme blockade, alone or combined with blockade of soluble epoxide hydrolase, on the course of congestive heart failure and occurrence of renal dysfunction in Ren-2 transgenic hypertensive rats with aorto-caval fistula

Glucose Homeostasis, Pancreatic Endocrine Function, and Outcomes in Advanced Heart Failure

Changes in Myocardial Composition and Conduction Properties in Rat Heart Failure Model Induced by Chronic Volume Overload

Inhibition of soluble epoxide hydrolase does not improve the course of congestive heart failure and the development of renal dysfunction in rats with volume overload induced by aorto-caval fistula

Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension

Proteomic and transcriptomic analysis of heart failure due to volume overload in a rat aorto-caval fistula model provides support for new potential therapeutic targets - monoamine oxidase A and transglutaminase 2